Septerna (SEPN) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Septerna (SEPN) has outperformed Vera Therapeutics (VERA) over the past year, gaining 51.1% versus a loss of 10.6%. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.84 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SEPN | VERA |
|---|---|---|
| Share price | $38.61 | $25.45 |
| Market cap | $1.84B | $1.84B |
| 1-day change | -1.51% | -4.86% |
| YTD return | +38.49% | -49.74% |
| 1-year return | +51.06% | -10.58% |
| 5-year return | — | -15.17% |
| EPS (TTM) | $-1.30 | $-5.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $45.95M | — |
| Revenue growth (YoY) | +4174.51% | — |
| Net income (latest FY) | $-48.88M | $-299.62M |
| Operating margin | -148.63% | — |
| Net margin | -106.37% | — |
| 52-week high | $53.34 | $56.05 |
| 52-week low | $22.78 | $25.08 |
| Distance from 52-week high | -27.62% | -54.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.38% | +180.39% |
| Average volume | 383.96K | 1.95M |
| Shares outstanding | 47.55M | 72.30M |
| Employees | 134 | 362 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SEPN has outperformed VERA by 61.6 percentage points over the past year.
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees
SEPN vs VERA FAQ
Which is bigger, Septerna or Vera Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.84B for Septerna (SEPN).
Which stock has performed better over the past year, SEPN or VERA?
SEPN returned +51.06% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Septerna and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.